Dev Indraja D, Puranik Ameya D, Rangarajan Venkatesh, Patra Sukriti, Purandare Nilendu, Sahu Arpita, Choudhary Amitkumar, Bhattacharya Kajari, Gupta Tejpal, Chatterjee Abhishek, Dasgupta Archya, Moiyadi Aliasgar, Shetty Prakash, Singh Vikas, Sridhar Epari, Sahay Ayushi, Shah Aekta, Ghosh Suchismita, Choudhury Sayak, Shah Sneha, Agrawal Archi
Depts of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Dr E Borges Marg, Parel, Mumbai 400012, India.
Radiodiagnosis, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Dr E Borges Marg, Parel, Mumbai 400012, India.
Explor Target Antitumor Ther. 2024;5(6):1289-1296. doi: 10.37349/etat.2024.00276. Epub 2024 Oct 31.
Fibroblast-activated protein (FAP) expression in glial cells is attributed to FAP-positive foci on tumor vessels and neoplastic cells. Preclinical and pilot studies have shown FAP expression in high-grade gliomas. We aimed at comparing PET imaging with FAP-inhibitor (FAPI-PET) with current standard, i.e., fluoro-ethyl tyrosine (FET) PET in post-treatment setting to differentiate recurrence and post-treatment changes. 6 patients with WHO Grade III and IV glioma who received standard treatment underwent Ga-68-FAPI-04 PET/CT (FAPI-PET/CT). Tracer uptake greater than background was considered positive. FET PET was performed and interpreted as per institutional standards, which formed the basis of treatment decision. There was concordance between FAPI expression and FET uptake in 5 patients suggestive of disease recurrence. There was no FAPI expression seen in 1 patient, in whom FET PET was suggestive of post-treatment changes. FAPI PET uptake correlated with amino acid expression to differentiate post treatment changes from recurrence in high-grade glial tumors; further validation with prospective study and histopathological confirmation is needed.
神经胶质细胞中纤维母细胞激活蛋白（FAP）的表达归因于肿瘤血管和肿瘤细胞上的FAP阳性病灶。临床前和试点研究已表明高级别胶质瘤中有FAP表达。我们旨在将FAP抑制剂PET成像（FAPI-PET）与当前标准，即氟代乙基酪氨酸（FET）PET在治疗后进行比较，以区分复发和治疗后改变。6例接受标准治疗的世界卫生组织III级和IV级胶质瘤患者接受了Ga-68-FAPI-04 PET/CT（FAPI-PET/CT）检查。示踪剂摄取高于本底被视为阳性。FET PET按照机构标准进行并解读，其构成了治疗决策的基础。5例患者中FAPI表达与FET摄取一致，提示疾病复发。1例患者未见FAPI表达，其FET PET提示为治疗后改变。FAPI PET摄取与氨基酸表达相关，以区分高级别胶质瘤治疗后改变与复发；需要通过前瞻性研究和组织病理学确认进行进一步验证。
